[Overview of U.S. stock market pre-market news: The NVIDIA crisis has stalled the rebound of technology stocks; SK Hynix’s HBM4 yield rate is reported to have exceeded 70%; China’s first oral GLP-1 weight loss drug has been approved for marketing] November 12th, the financial news of the U.S. stock market that investors need to focus on is as follows: 1. The three major U.S. stock index futures rose or fell mixedly. Dow Jones futures rose 0.09%, S&P 500 futures fell 0.46%, and Nasdaq 100 futures fell 1.04%. 2. International oil prices fell slightly. WTI crude oil futures prices fell 0.90% to US$85.749/barrel; Brent crude oil futures prices fell 0.69% to US$92.124/barrel. 3. International gold and silver spot prices fell collectively. Spot gold prices fell 1.27% to US$3,936.94 per ounce; spot silver prices fell by 1.37% to US$50.94 per ounce. 4. The three major European stock indexes all rose. Britain's FTSE 100 index rose 0.23%, France's CAC40 index rose 0.63%, and Germany's DAX30 index rose 0.62%. 5. Nvidia’s internal turmoil may disrupt AI trading. Nvidia fell nearly 8% before the market opened, Micron Technology fell more than 4%, and Intel and TSMC fell about 3%. However, its competitors AMD and Broadcom rose slightly. 6. Nebius, an AI computing power leasing company, said that the first batch of NVIDIA Vera Rubin systems have been launched and are being integrated into the Nebius AI Cloud and are ready to be deployed to customers. The company’s AI cloud revenue in the third quarter was US$973.8 million, a year-on-year increase of 643%. 7. It is reported that SK Hynix’s HBM4 yield rate has recently exceeded 70%. However, SK Hynix has not officially announced specific yield data. 8. Eli Lilly’s Class 1 new drug Orflugliflozin Calcium Tablets (trade name: Muyuda) was approved for marketing in China. It is the first oral GLP-1 weight loss drug approved in China. 9. Vanda Research, a research institution, predicts that Anthropic will attract about US$250 million in net buying from retail investors on its first day of listing, which may be double SpaceX’s previous record. 10. OpenAI is reported to have lowered its IPO target valuation to US$1.25 trillion and cut its financing target by one-third.